What is Geno?
Geno, formerly Genomatica, is at the forefront of harnessing synthetic biology to revolutionize the production of everyday products and materials. The company leverages clean manufacturing processes, utilizing plants and waste streams as alternatives to fossil fuels and unsustainable sources like palm oil. Geno's technology enables the development of higher-performance, more sustainable ingredients for a wide array of consumer goods. The company has already successfully commercialized products for plastics, spandex, and personal care items, with ongoing development for materials such as nylon and household cleaners. This focus on bio-based manufacturing positions Geno as a key player in the transition towards a more circular and sustainable economy.
How much funding has Geno raised?
Geno has raised a total of $333.1M across 7 funding rounds:
Series A
$4M
Series B
$20M
Series C
$15M
Unspecified
$45M
Unspecified
$41.1M
Unspecified
$90M
Unspecified
$118M
Series A (2002): $4M, investors not publicly disclosed
Series B (2007): $20M led by Mohr Davidow Ventures and Draper Fisher Jurvetson (DFJ)
Series C (2010): $15M supported by Alloy Ventures, TPG Biotechnology Partners, Mohr Davidow Ventures, and Draper Fisher Jurvetson
Unspecified (2011): $45M, investors not publicly disclosed
Unspecified (2012): $41.1M, investors not publicly disclosed
Unspecified (2018): $90M with participation from Ginkgo Bioworks, Viking Global Investors, and Casdin Capital
Unspecified (2021): $118M led by Novo Holdings
Key Investors in Geno
Novo Holdings
Novo Holdings is a Danish investment company wholly owned by the Novo Nordisk Foundation, focusing on life sciences and biotechnology investments.
Mohr Davidow Ventures
Mohr Davidow Ventures is a venture capital firm that supports innovative companies, particularly those focused on productivity enhancement and significant market opportunities.
Draper Fisher Jurvetson (DFJ)
Draper Fisher Jurvetson is a global venture capital firm known for backing extraordinary entrepreneurs and disruptive technologies across various sectors.
What's next for Geno?
The recent major strategic investment signals a pivotal growth phase for Geno. This capital infusion is expected to accelerate the company's expansion of its commercialized product lines and further its research and development into new sustainable materials. Geno's commitment to replacing traditional, petroleum-based manufacturing with bio-based alternatives aligns with increasing global demand for environmentally conscious products. The company's trajectory suggests a continued focus on scaling its proprietary technology and forging strategic partnerships to broaden market penetration, solidifying its role as a leader in the bio-manufacturing industry.
See full Geno company page
